

# Delivery of magnetic nanoparticles to lung cancer cells via polarized macrophages: A riveting tale of a bio-inspired phenomenon

Vinit V. Agnihotri<sup>a,c,\*</sup>, Ashish P. Gorle<sup>b</sup>

<sup>a</sup> Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur- 425405, Dist. Dhule, Maharashtra, India

<sup>b</sup> Department of Pharmaceutical Technology, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur- 425405, Dist. Dhule, Maharashtra, India

<sup>c</sup> Department of Pharmaceutics, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule -424 001, Maharashtra, India

## ARTICLE INFO

### Keywords:

Magnetic nanoparticles  
Polarized macrophages  
Phagocytosis  
M1 Phenotype  
Tumor microenvironment

## ABSTRACT

Macrophages critically influences the tumor progression. The bio-carriers like macrophages have proven successful in circumventing this mammoth challenge by selectively infiltrating cancerous cells with anticancer drugs. Moreover, macrophage phenotypes have been found to have a key role in early phase of angiogenesis in the lungs. Phenotypic macrophages will serve to billet the iron, which has been found to have cancer cell-killing proficiency. Recent studies have shown the modulation of the molecular mechanism for tumor suppression by iron oxide (IO) nanoparticles. In addition, previous research focus on the interlink connections of iron and macrophages concerning macrophage polarization and consequent tumor suppression. However, we found that the initiation of the molecular response by external macrophages carrying anticancer agents has an exceptional breach in current drug delivery technology. We assume that macrophages carrying IO nanoparticles prepared by insemination-like formulation strategy to initiate the three-way response 1) directly invading the tumors with *in vitro* polarized macrophages; 2) Simultaneously delivering IO nanoparticles to augment the tumor suppression, and 3) IO deposition in TME further encourages polarization from M2 to proinflammatory M1 macrophages. Therefore, in the present study, we hypothesize that magnetic nanoparticles that are entrapped in phenotypic polarized macrophages will have striking potential to target lung cancer. In this hypothesis, we discussed the molecular interplay of iron and macrophages, *in-vitro* internalization of iron nanoparticles, and *in vivo* release inside the tumor cell.

## Introduction

The second highest malignancy prevalence in the world is lung cancer [1]. A major challenge in treating lung cancer is drug resistance. As cancer advances, the tumor microenvironment (TME) may become resistant to drugs [2]. The bio-carriers like macrophages have proven successful in circumventing this mammoth challenge by selectively infiltrating cancerous cells with anticancer drugs[3–5]. In lung cancer, macrophages portray a crucial role in the pulmonary defense and

inflammatory response that restrain the initial tumor growth[6]. At the beginning of tumorigenesis, alveolar macrophages (AMs) are found in the airspaces of the pulmonary voids and be present in the lower respiratory tract[7]. According to the research, the specific phenotype of AMs appears to have a significant role in the early phases of angiogenesis in the lungs[8]. Macrophages differentiate into proinflammatory M1 cells in response to precursors like iron[9]. A study by Costa da Silva, Milene revealed that patients with non-small cell lung cancer (NSCLC) who have detectable iron in their TME have smaller malignant cells

**Abbreviations:** TIME, Tumor immune microenvironment; TME, Tumor microenvironment; AMs, Alveolar macrophages; NSCLC, Non-small cell lung cancer; MRI, Magnetic Resonance Imaging; CXCL, Chemokine Ligand; ROS, Reactive oxygen species; TLR<sub>4</sub>, Toll-like Receptor 4; MAPK, mitogen-activating protein kinase; LPS, Lipopolysaccharide; IFN, Interferon; JAK, Janus Kinase; STAT1, Signal Transducer And Activator Of Transcription 1; IRF3, Interferon Regulatory Factor 3; iNOS, Inducible Nitric Oxide Synthase; DAMP, Damage-Associated Molecular Pattern; THP-1, Tamm-Horsfall Protein 1; RPMI, Roswell Park Memorial Institute medium; AFM, Atomic Force Microscopy; FTIR, Fourier Transform Infrared; MMAD, Mass Median Aerodynamic Diameter; FPF, Fine Particle Fraction; BAL, bronchoalveolar lavage; FPN, Ferroportin; DMT1, Divalent Metal Transporter 1; MZF1, Myeloid Zinc Finger 1; Nrf2, Nuclear Factor Erythroid 2-related Factor 2; LIP, Labile Iron Pool; EGFR, Epidermal Growth Factor Receptor; Tfr1, Transferrin Receptor 1; E1A, Early Region 1A Gene Tumor immune microenvironment.

\* Corresponding author at: Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist-Dhule-425405, Maharashtra, India.


E-mail address: [vinit.agnihotri@svkm.ac.in](mailto:vinit.agnihotri@svkm.ac.in) (V.V. Agnihotri).

<https://doi.org/10.1016/j.mehy.2023.111154>

Received 5 May 2023; Received in revised form 15 August 2023; Accepted 26 August 2023

Available online 28 August 2023

0306-9877/© 2023 Elsevier Ltd. All rights reserved.



Already have a manuscript?  
Use our Manuscript Matcher to find the best relevant journals!

[Find a Match](#)

Filters [Clear All](#)

- Web of Science Coverage
- Open Access
- Category
- Country / Region
- Language
- Frequency
- Journal Citation Reports

### Refine Your Search Results

Medical Hypotheses [Search](#) Sort By: Relevancy

Search Results  
Found 1,175 results (Page 1) [Share These Results](#)

#### Exact Match Found

**MEDICAL HYPOTHESES**

Publisher: ELSEVIER, RADARWEG 29, AMSTERDAM, Netherlands, 1043 NX  
ISSN / eISSN: 0306-9877 / 1532-2777  
Web of Science Core Collection: Science Citation Index Expanded  
Additional Web of Science Indexes: Biological Abstracts | BIOSIS Previews | Current Contents Clinical Medicine | Current Contents Life Sciences | Essential Science Indicators

[Share This Journal](#) [View profile page](#)  
\* Requires free login.

#### Other Possible Matches

**ADVANCES IN MEDICAL EDUCATION AND PRACTICE**

Publisher: DOVE MEDICAL PRESS LTD, PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752  
ISSN / eISSN: 1179-7758